Pipeline news

• Marinus Pharmaceuticals Adds $21M Series C

  07 January 2013

  

  Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.

• CoDa Therapeutics Completes $49 Million Fund Raising

  24 July 2012

  

  CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.

• Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

  06 October 2011

  Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.

• Marinus Pharmaceuticals Issued Patent for Ganaxolone

  29 April 2011

  

  Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.  

• CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.

  18 April 2011

  

  San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.

• Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

  17 April 2011

  

  Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.